nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—EPHB2—brainstem—meningioma	0.00991	0.0336	CbGeAlD
Nilotinib—MAPK8—brainstem—meningioma	0.00792	0.0269	CbGeAlD
Nilotinib—EPHB3—brainstem—meningioma	0.00653	0.0222	CbGeAlD
Nilotinib—CDC42BPB—medulla oblongata—meningioma	0.00611	0.0207	CbGeAlD
Nilotinib—MAPK8—medulla oblongata—meningioma	0.00552	0.0187	CbGeAlD
Nilotinib—EPHA4—brainstem—meningioma	0.00546	0.0185	CbGeAlD
Nilotinib—CDC42BPB—spinal cord—meningioma	0.00545	0.0185	CbGeAlD
Nilotinib—MAPK14—brainstem—meningioma	0.00503	0.0171	CbGeAlD
Nilotinib—MAPK8—spinal cord—meningioma	0.00492	0.0167	CbGeAlD
Nilotinib—EPHA8—cerebellum—meningioma	0.00468	0.0159	CbGeAlD
Nilotinib—MAPK11—cerebellum—meningioma	0.00435	0.0148	CbGeAlD
Nilotinib—CDC42BPB—cerebellum—meningioma	0.00432	0.0146	CbGeAlD
Nilotinib—HCK—medulla oblongata—meningioma	0.00419	0.0142	CbGeAlD
Nilotinib—EPHB3—spinal cord—meningioma	0.00406	0.0138	CbGeAlD
Nilotinib—EPHB2—brain—meningioma	0.00397	0.0135	CbGeAlD
Nilotinib—MAPK8—cerebellum—meningioma	0.00391	0.0132	CbGeAlD
Nilotinib—EPHA4—medulla oblongata—meningioma	0.0038	0.0129	CbGeAlD
Nilotinib—EPHA8—brain—meningioma	0.0038	0.0129	CbGeAlD
Nilotinib—HCK—spinal cord—meningioma	0.00373	0.0127	CbGeAlD
Nilotinib—MAP2K5—brainstem—meningioma	0.00373	0.0127	CbGeAlD
Nilotinib—MAPK11—brain—meningioma	0.00354	0.012	CbGeAlD
Nilotinib—CDC42BPB—brain—meningioma	0.00351	0.0119	CbGeAlD
Nilotinib—CA14—medulla oblongata—meningioma	0.00341	0.0116	CbGeAlD
Nilotinib—TIE1—cerebellum—meningioma	0.00339	0.0115	CbGeAlD
Nilotinib—EPHB4—medulla oblongata—meningioma	0.00333	0.0113	CbGeAlD
Nilotinib—EPHA3—brain—meningioma	0.00332	0.0113	CbGeAlD
Nilotinib—KIT—brainstem—meningioma	0.00331	0.0112	CbGeAlD
Nilotinib—BRAF—cerebellum—meningioma	0.00325	0.011	CbGeAlD
Nilotinib—EPHB3—cerebellum—meningioma	0.00322	0.0109	CbGeAlD
Nilotinib—TEK—medulla oblongata—meningioma	0.00318	0.0108	CbGeAlD
Nilotinib—MAPK8—brain—meningioma	0.00317	0.0108	CbGeAlD
Nilotinib—EPHA6—brain—meningioma	0.00317	0.0108	CbGeAlD
Nilotinib—MAPK14—spinal cord—meningioma	0.00313	0.0106	CbGeAlD
Nilotinib—CA14—spinal cord—meningioma	0.00304	0.0103	CbGeAlD
Nilotinib—EPHB6—medulla oblongata—meningioma	0.00304	0.0103	CbGeAlD
Nilotinib—EPHB4—spinal cord—meningioma	0.00297	0.0101	CbGeAlD
Nilotinib—ABL2—cerebellum—meningioma	0.00294	0.00998	CbGeAlD
Nilotinib—LYN—brain—meningioma	0.00293	0.00993	CbGeAlD
Nilotinib—CA7—cerebellum—meningioma	0.0029	0.00982	CbGeAlD
Nilotinib—MAP4K1—brain—meningioma	0.00288	0.00978	CbGeAlD
Nilotinib—ABL1—brainstem—meningioma	0.00288	0.00976	CbGeAlD
Nilotinib—TEK—spinal cord—meningioma	0.00284	0.00963	CbGeAlD
Nilotinib—TIE1—brain—meningioma	0.00275	0.00933	CbGeAlD
Nilotinib—EPHB6—spinal cord—meningioma	0.00271	0.0092	CbGeAlD
Nilotinib—EPHA4—cerebellum—meningioma	0.00269	0.00912	CbGeAlD
Nilotinib—BRAF—brain—meningioma	0.00264	0.00894	CbGeAlD
Nilotinib—EPHB3—brain—meningioma	0.00262	0.00887	CbGeAlD
Nilotinib—MAP2K5—medulla oblongata—meningioma	0.0026	0.00882	CbGeAlD
Nilotinib—PDGFRA—spinal cord—meningioma	0.00257	0.00872	CbGeAlD
Nilotinib—CA9—cerebellum—meningioma	0.00254	0.00863	CbGeAlD
Nilotinib—CSF1R—medulla oblongata—meningioma	0.00254	0.00861	CbGeAlD
Nilotinib—MAPK14—cerebellum—meningioma	0.00248	0.00841	CbGeAlD
Nilotinib—CA14—cerebellum—meningioma	0.00241	0.00818	CbGeAlD
Nilotinib—HCK—brain—meningioma	0.0024	0.00815	CbGeAlD
Nilotinib—ABL2—brain—meningioma	0.00239	0.0081	CbGeAlD
Nilotinib—CA4—brainstem—meningioma	0.00236	0.00802	CbGeAlD
Nilotinib—CA7—brain—meningioma	0.00235	0.00798	CbGeAlD
Nilotinib—EPHB4—cerebellum—meningioma	0.00235	0.00798	CbGeAlD
Nilotinib—MAP2K5—spinal cord—meningioma	0.00232	0.00787	CbGeAlD
Nilotinib—KIT—medulla oblongata—meningioma	0.0023	0.00782	CbGeAlD
Nilotinib—CSF1R—spinal cord—meningioma	0.00226	0.00768	CbGeAlD
Nilotinib—PDGFRB—medulla oblongata—meningioma	0.00225	0.00764	CbGeAlD
Nilotinib—TEK—cerebellum—meningioma	0.00225	0.00763	CbGeAlD
Nilotinib—EPHA4—brain—meningioma	0.00218	0.00741	CbGeAlD
Nilotinib—CA3—brain—meningioma	0.00216	0.00732	CbGeAlD
Nilotinib—EPHB6—cerebellum—meningioma	0.00215	0.00729	CbGeAlD
Nilotinib—KIT—spinal cord—meningioma	0.00206	0.00697	CbGeAlD
Nilotinib—PDGFRA—cerebellum—meningioma	0.00204	0.00692	CbGeAlD
Nilotinib—MAPK14—brain—meningioma	0.00201	0.00683	CbGeAlD
Nilotinib—PDGFRB—spinal cord—meningioma	0.00201	0.00681	CbGeAlD
Nilotinib—ABL1—medulla oblongata—meningioma	0.00201	0.00681	CbGeAlD
Nilotinib—FGR—brain—meningioma	0.00201	0.00681	CbGeAlD
Nilotinib—CA14—brain—meningioma	0.00196	0.00665	CbGeAlD
Nilotinib—CA2—brainstem—meningioma	0.00196	0.00665	CbGeAlD
Nilotinib—EPHB4—brain—meningioma	0.00191	0.00648	CbGeAlD
Nilotinib—CA1—spinal cord—meningioma	0.00188	0.00638	CbGeAlD
Nilotinib—EPHA2—brain—meningioma	0.00187	0.00636	CbGeAlD
Nilotinib—MAP2K5—cerebellum—meningioma	0.00184	0.00624	CbGeAlD
Nilotinib—TEK—brain—meningioma	0.00183	0.0062	CbGeAlD
Nilotinib—CSF1R—cerebellum—meningioma	0.00179	0.00609	CbGeAlD
Nilotinib—ABL1—spinal cord—meningioma	0.00179	0.00607	CbGeAlD
Nilotinib—EPHB6—brain—meningioma	0.00175	0.00593	CbGeAlD
Nilotinib—PDGFRA—brain—meningioma	0.00166	0.00562	CbGeAlD
Nilotinib—CA4—medulla oblongata—meningioma	0.00165	0.00559	CbGeAlD
Nilotinib—KIT—cerebellum—meningioma	0.00163	0.00553	CbGeAlD
Nilotinib—PDGFRB—cerebellum—meningioma	0.00159	0.0054	CbGeAlD
Nilotinib—CA12—brain—meningioma	0.00153	0.00518	CbGeAlD
Nilotinib—MAP2K5—brain—meningioma	0.00149	0.00507	CbGeAlD
Nilotinib—CA4—spinal cord—meningioma	0.00147	0.00498	CbGeAlD
Nilotinib—CSF1R—brain—meningioma	0.00146	0.00495	CbGeAlD
Nilotinib—ABL1—cerebellum—meningioma	0.00142	0.00481	CbGeAlD
Nilotinib—CA2—medulla oblongata—meningioma	0.00137	0.00463	CbGeAlD
Nilotinib—KIT—brain—meningioma	0.00132	0.00449	CbGeAlD
Nilotinib—PDGFRB—brain—meningioma	0.00129	0.00439	CbGeAlD
Nilotinib—ABCG2—medulla oblongata—meningioma	0.00127	0.00429	CbGeAlD
Nilotinib—CYP2D6—brainstem—meningioma	0.00124	0.00422	CbGeAlD
Nilotinib—CA2—spinal cord—meningioma	0.00122	0.00413	CbGeAlD
Nilotinib—CA1—brain—meningioma	0.00121	0.00411	CbGeAlD
Nilotinib—CA4—cerebellum—meningioma	0.00116	0.00395	CbGeAlD
Nilotinib—ABL1—brain—meningioma	0.00115	0.00391	CbGeAlD
Nilotinib—ABCG2—spinal cord—meningioma	0.00113	0.00383	CbGeAlD
Nilotinib—CA2—cerebellum—meningioma	0.000966	0.00328	CbGeAlD
Nilotinib—CA4—brain—meningioma	0.000946	0.00321	CbGeAlD
Nilotinib—ABCG2—cerebellum—meningioma	0.000895	0.00303	CbGeAlD
Nilotinib—CA2—brain—meningioma	0.000785	0.00266	CbGeAlD
Nilotinib—CYP2C8—brain—meningioma	0.000747	0.00254	CbGeAlD
Nilotinib—ABCG2—brain—meningioma	0.000727	0.00247	CbGeAlD
Nilotinib—CYP2B6—brain—meningioma	0.00067	0.00227	CbGeAlD
Nilotinib—ABCB1—medulla oblongata—meningioma	0.000624	0.00212	CbGeAlD
Nilotinib—CYP2D6—cerebellum—meningioma	0.000613	0.00208	CbGeAlD
Nilotinib—ABCB1—spinal cord—meningioma	0.000556	0.00189	CbGeAlD
Nilotinib—CYP2D6—brain—meningioma	0.000498	0.00169	CbGeAlD
Nilotinib—ABCB1—cerebellum—meningioma	0.000441	0.0015	CbGeAlD
Nilotinib—ABCB1—brain—meningioma	0.000358	0.00122	CbGeAlD
Nilotinib—KIT—Immune System—PDGFB—meningioma	0.000121	0.000171	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—meningioma	0.000121	0.000171	CbGpPWpGaD
Nilotinib—LCK—Signaling by FGFR in disease—AKT1—meningioma	0.00012	0.000171	CbGpPWpGaD
Nilotinib—LCK—Fc epsilon receptor (FCERI) signaling—AKT1—meningioma	0.00012	0.000171	CbGpPWpGaD
Nilotinib—LCK—DAP12 interactions—AKT1—meningioma	0.00012	0.000171	CbGpPWpGaD
Nilotinib—KIT—Signaling by NGF—AKT1—meningioma	0.00012	0.00017	CbGpPWpGaD
Nilotinib—MAPK14—Cellular responses to stress—TP53—meningioma	0.00012	0.00017	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR—AKT1—meningioma	0.000119	0.000169	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—SMO—meningioma	0.000119	0.000168	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—ERBB2—meningioma	0.000119	0.000168	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—PTEN—meningioma	0.000119	0.000168	CbGpPWpGaD
Nilotinib—LCK—Signaling by EGFR in Cancer—AKT1—meningioma	0.000118	0.000168	CbGpPWpGaD
Nilotinib—LCK—Signaling by PDGF—AKT1—meningioma	0.000118	0.000167	CbGpPWpGaD
Nilotinib—MAPK14—Metabolism of mRNA—AKT1—meningioma	0.000117	0.000166	CbGpPWpGaD
Nilotinib—CA7—Metabolism—PTEN—meningioma	0.000117	0.000166	CbGpPWpGaD
Nilotinib—MAPK14—Platelet activation, signaling and aggregation—AKT1—meningioma	0.000116	0.000165	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—SMO—meningioma	0.000116	0.000165	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—ERBB2—meningioma	0.000116	0.000165	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—ERBB2—meningioma	0.000115	0.000164	CbGpPWpGaD
Nilotinib—CA3—Metabolism—AKT1—meningioma	0.000115	0.000163	CbGpPWpGaD
Nilotinib—HCK—Disease—ERBB2—meningioma	0.000115	0.000163	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PDGFB—meningioma	0.000114	0.000162	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PGR—meningioma	0.000114	0.000161	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—ERBB2—meningioma	0.000114	0.000161	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—PTEN—meningioma	0.000114	0.000161	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling by NGF—AKT1—meningioma	0.000113	0.000161	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—ERBB2—meningioma	0.000113	0.00016	CbGpPWpGaD
Nilotinib—BLK—Immune System—ERBB2—meningioma	0.000113	0.00016	CbGpPWpGaD
Nilotinib—FGR—Immune System—ERBB2—meningioma	0.000112	0.000159	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—PTEN—meningioma	0.000112	0.000159	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TSHB—meningioma	0.000112	0.000159	CbGpPWpGaD
Nilotinib—KIT—Disease—PDGFB—meningioma	0.000111	0.000158	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PGR—meningioma	0.000111	0.000158	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—ERBB2—meningioma	0.000111	0.000158	CbGpPWpGaD
Nilotinib—LCK—B Cell Activation—AKT1—meningioma	0.000111	0.000158	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HES1—meningioma	0.000111	0.000158	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—SMO—meningioma	0.00011	0.000156	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—ERBB2—meningioma	0.00011	0.000156	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—ALAD—meningioma	0.000109	0.000155	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PDGFB—meningioma	0.000109	0.000154	CbGpPWpGaD
Nilotinib—CA12—Metabolism—PTEN—meningioma	0.000109	0.000154	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—PTEN—meningioma	0.000108	0.000153	CbGpPWpGaD
Nilotinib—LCK—NGF signalling via TRKA from the plasma membrane—AKT1—meningioma	0.000107	0.000151	CbGpPWpGaD
Nilotinib—HCK—Immune System—PTEN—meningioma	0.000106	0.00015	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PGR—meningioma	0.000106	0.00015	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PDGFB—meningioma	0.000106	0.00015	CbGpPWpGaD
Nilotinib—FGR—Hemostasis—AKT1—meningioma	0.000105	0.000149	CbGpPWpGaD
Nilotinib—HCK—Innate Immune System—AKT1—meningioma	0.000105	0.000149	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PDGFB—meningioma	0.000103	0.000147	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PDGFB—meningioma	0.000103	0.000146	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—meningioma	0.000103	0.000146	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ALAD—meningioma	0.000103	0.000146	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling by NGF—AKT1—meningioma	0.000102	0.000145	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ALAD—meningioma	0.000102	0.000144	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HES1—meningioma	0.000101	0.000144	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—PTEN—meningioma	0.000101	0.000143	CbGpPWpGaD
Nilotinib—LYN—Immune System—PDGFB—meningioma	0.000101	0.000143	CbGpPWpGaD
Nilotinib—LCK—Platelet activation, signaling and aggregation—AKT1—meningioma	0.000101	0.000143	CbGpPWpGaD
Nilotinib—MAPK14—Metabolism of RNA—AKT1—meningioma	0.0001	0.000142	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PDGFB—meningioma	0.0001	0.000142	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HES1—meningioma	0.0001	0.000142	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—PTEN—meningioma	9.89e-05	0.00014	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—PTEN—meningioma	9.85e-05	0.00014	CbGpPWpGaD
Nilotinib—HCK—Disease—PTEN—meningioma	9.79e-05	0.000139	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—PTEN—meningioma	9.7e-05	0.000138	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—PTEN—meningioma	9.61e-05	0.000136	CbGpPWpGaD
Nilotinib—BLK—Immune System—PTEN—meningioma	9.61e-05	0.000136	CbGpPWpGaD
Nilotinib—FGR—Immune System—PTEN—meningioma	9.58e-05	0.000136	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PDGFB—meningioma	9.56e-05	0.000136	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—SMO—meningioma	9.53e-05	0.000135	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—TSHB—meningioma	9.52e-05	0.000135	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—ERBB2—meningioma	9.51e-05	0.000135	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PDGFB—meningioma	9.51e-05	0.000135	CbGpPWpGaD
Nilotinib—MAPK8—Innate Immune System—AKT1—meningioma	9.51e-05	0.000135	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—PTEN—meningioma	9.5e-05	0.000135	CbGpPWpGaD
Nilotinib—MAPK14—Signaling by NGF—AKT1—meningioma	9.48e-05	0.000134	CbGpPWpGaD
Nilotinib—FGR—Innate Immune System—AKT1—meningioma	9.47e-05	0.000134	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—PTEN—meningioma	9.38e-05	0.000133	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PGR—meningioma	9.14e-05	0.00013	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—ERBB2—meningioma	9.13e-05	0.00013	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HES1—meningioma	9.13e-05	0.000129	CbGpPWpGaD
Nilotinib—BLK—Adaptive Immune System—AKT1—meningioma	9.13e-05	0.000129	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—ERBB2—meningioma	8.98e-05	0.000127	CbGpPWpGaD
Nilotinib—LCK—Disease—HES1—meningioma	8.92e-05	0.000127	CbGpPWpGaD
Nilotinib—CA4—Metabolism—PTEN—meningioma	8.66e-05	0.000123	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PDGFB—meningioma	8.66e-05	0.000123	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HES1—meningioma	8.64e-05	0.000123	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PDGFB—meningioma	8.58e-05	0.000122	CbGpPWpGaD
Nilotinib—MAPK11—Developmental Biology—AKT1—meningioma	8.58e-05	0.000122	CbGpPWpGaD
Nilotinib—CA2—Metabolism—PTEN—meningioma	8.31e-05	0.000118	CbGpPWpGaD
Nilotinib—LCK—Immune System—PDGFB—meningioma	8.26e-05	0.000117	CbGpPWpGaD
Nilotinib—BRAF—Disease—ERBB2—meningioma	8.21e-05	0.000116	CbGpPWpGaD
Nilotinib—LCK—Signaling by NGF—AKT1—meningioma	8.19e-05	0.000116	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—PTEN—meningioma	8.11e-05	0.000115	CbGpPWpGaD
Nilotinib—KIT—Immune System—ERBB2—meningioma	8.09e-05	0.000115	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—TSHB—meningioma	8.06e-05	0.000114	CbGpPWpGaD
Nilotinib—CA1—Metabolism—PTEN—meningioma	7.96e-05	0.000113	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PDGFB—meningioma	7.81e-05	0.000111	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—PTEN—meningioma	7.79e-05	0.00011	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HES1—meningioma	7.79e-05	0.00011	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—ERBB2—meningioma	7.66e-05	0.000109	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—PTEN—meningioma	7.65e-05	0.000109	CbGpPWpGaD
Nilotinib—LCK—Disease—PDGFB—meningioma	7.63e-05	0.000108	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HES1—meningioma	7.62e-05	0.000108	CbGpPWpGaD
Nilotinib—MAPK11—Innate Immune System—AKT1—meningioma	7.57e-05	0.000107	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—TP53—meningioma	7.5e-05	0.000106	CbGpPWpGaD
Nilotinib—KIT—Disease—ERBB2—meningioma	7.47e-05	0.000106	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—TP53—meningioma	7.47e-05	0.000106	CbGpPWpGaD
Nilotinib—CA14—Metabolism—AKT1—meningioma	7.43e-05	0.000105	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PDGFB—meningioma	7.39e-05	0.000105	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—ERBB2—meningioma	7.28e-05	0.000103	CbGpPWpGaD
Nilotinib—CA6—Metabolism—AKT1—meningioma	7.24e-05	0.000103	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HES1—meningioma	7.23e-05	0.000102	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—TP53—meningioma	7.11e-05	0.000101	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—ERBB2—meningioma	7.07e-05	0.0001	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TSHB—meningioma	7.02e-05	9.96e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—meningioma	7.02e-05	9.96e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—PTEN—meningioma	7e-05	9.93e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—PTEN—meningioma	7e-05	9.93e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—ERBB2—meningioma	6.93e-05	9.82e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—ERBB2—meningioma	6.9e-05	9.79e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—PTEN—meningioma	6.9e-05	9.79e-05	CbGpPWpGaD
Nilotinib—KIT—Innate Immune System—AKT1—meningioma	6.83e-05	9.68e-05	CbGpPWpGaD
Nilotinib—CA7—Metabolism—AKT1—meningioma	6.76e-05	9.58e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—ERBB2—meningioma	6.76e-05	9.58e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—ERBB2—meningioma	6.73e-05	9.54e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ALAD—meningioma	6.71e-05	9.52e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PDGFB—meningioma	6.66e-05	9.44e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TSHB—meningioma	6.62e-05	9.38e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TSHB—meningioma	6.56e-05	9.3e-05	CbGpPWpGaD
Nilotinib—KIT—Adaptive Immune System—AKT1—meningioma	6.56e-05	9.3e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—PTEN—meningioma	6.53e-05	9.27e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PDGFB—meningioma	6.52e-05	9.24e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Innate Immune System—AKT1—meningioma	6.47e-05	9.17e-05	CbGpPWpGaD
Nilotinib—LYN—Developmental Biology—AKT1—meningioma	6.46e-05	9.16e-05	CbGpPWpGaD
Nilotinib—ABL1—Developmental Biology—AKT1—meningioma	6.43e-05	9.11e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—ERBB2—meningioma	6.41e-05	9.08e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—ERBB2—meningioma	6.37e-05	9.04e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—PTEN—meningioma	6.37e-05	9.04e-05	CbGpPWpGaD
Nilotinib—LYN—Hemostasis—AKT1—meningioma	6.33e-05	8.98e-05	CbGpPWpGaD
Nilotinib—ABL1—Hemostasis—AKT1—meningioma	6.3e-05	8.94e-05	CbGpPWpGaD
Nilotinib—CA12—Metabolism—AKT1—meningioma	6.26e-05	8.88e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HES1—meningioma	6.25e-05	8.86e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—PTEN—meningioma	6.21e-05	8.81e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Adaptive Immune System—AKT1—meningioma	6.21e-05	8.8e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PDGFB—meningioma	6.18e-05	8.76e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—TP53—meningioma	6.15e-05	8.72e-05	CbGpPWpGaD
Nilotinib—MAPK14—Developmental Biology—AKT1—meningioma	6.12e-05	8.68e-05	CbGpPWpGaD
Nilotinib—HCK—Immune System—AKT1—meningioma	6.11e-05	8.67e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—PTEN—meningioma	6.03e-05	8.55e-05	CbGpPWpGaD
Nilotinib—MAPK14—Hemostasis—AKT1—meningioma	6e-05	8.51e-05	CbGpPWpGaD
Nilotinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—meningioma	5.93e-05	8.41e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—PTEN—meningioma	5.91e-05	8.37e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—PTEN—meningioma	5.89e-05	8.35e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Innate Immune System—AKT1—meningioma	5.82e-05	8.26e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—ERBB2—meningioma	5.8e-05	8.23e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—PTEN—meningioma	5.76e-05	8.17e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—ERBB2—meningioma	5.75e-05	8.15e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PTEN—meningioma	5.74e-05	8.13e-05	CbGpPWpGaD
Nilotinib—LYN—Innate Immune System—AKT1—meningioma	5.7e-05	8.09e-05	CbGpPWpGaD
Nilotinib—ABL1—Innate Immune System—AKT1—meningioma	5.68e-05	8.05e-05	CbGpPWpGaD
Nilotinib—HCK—Disease—AKT1—meningioma	5.64e-05	8e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Adaptive Immune System—AKT1—meningioma	5.59e-05	7.93e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—ERBB2—meningioma	5.54e-05	7.86e-05	CbGpPWpGaD
Nilotinib—BLK—Immune System—AKT1—meningioma	5.54e-05	7.85e-05	CbGpPWpGaD
Nilotinib—MAPK8—Immune System—AKT1—meningioma	5.54e-05	7.85e-05	CbGpPWpGaD
Nilotinib—FGR—Immune System—AKT1—meningioma	5.52e-05	7.83e-05	CbGpPWpGaD
Nilotinib—LYN—Adaptive Immune System—AKT1—meningioma	5.48e-05	7.76e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PTEN—meningioma	5.46e-05	7.75e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PTEN—meningioma	5.43e-05	7.71e-05	CbGpPWpGaD
Nilotinib—MAPK14—Innate Immune System—AKT1—meningioma	5.41e-05	7.67e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PDGFB—meningioma	5.34e-05	7.58e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—ERBB2—meningioma	5.23e-05	7.42e-05	CbGpPWpGaD
Nilotinib—LCK—Hemostasis—AKT1—meningioma	5.19e-05	7.36e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—ERBB2—meningioma	5.11e-05	7.25e-05	CbGpPWpGaD
Nilotinib—CA4—Metabolism—AKT1—meningioma	4.99e-05	7.08e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—ERBB2—meningioma	4.95e-05	7.02e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PTEN—meningioma	4.95e-05	7.02e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—meningioma	4.93e-05	6.99e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PTEN—meningioma	4.9e-05	6.95e-05	CbGpPWpGaD
Nilotinib—CA2—Metabolism—AKT1—meningioma	4.79e-05	6.79e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—PTEN—meningioma	4.72e-05	6.7e-05	CbGpPWpGaD
Nilotinib—LCK—Innate Immune System—AKT1—meningioma	4.67e-05	6.63e-05	CbGpPWpGaD
Nilotinib—CA1—Metabolism—AKT1—meningioma	4.59e-05	6.51e-05	CbGpPWpGaD
Nilotinib—LCK—Adaptive Immune System—AKT1—meningioma	4.49e-05	6.36e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—ERBB2—meningioma	4.46e-05	6.33e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PTEN—meningioma	4.46e-05	6.33e-05	CbGpPWpGaD
Nilotinib—MAPK11—Immune System—AKT1—meningioma	4.41e-05	6.26e-05	CbGpPWpGaD
Nilotinib—MAPK11—Gene Expression—AKT1—meningioma	4.39e-05	6.22e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—ERBB2—meningioma	4.37e-05	6.2e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—PTEN—meningioma	4.36e-05	6.18e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TSHB—meningioma	4.33e-05	6.13e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—TP53—meningioma	4.24e-05	6.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PTEN—meningioma	4.22e-05	5.99e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PTEN—meningioma	4.17e-05	5.91e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—ERBB2—meningioma	4.14e-05	5.87e-05	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—meningioma	4.03e-05	5.72e-05	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—meningioma	4.03e-05	5.72e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—meningioma	4.03e-05	5.72e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—meningioma	4.01e-05	5.69e-05	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—meningioma	3.98e-05	5.64e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—meningioma	3.81e-05	5.4e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—meningioma	3.77e-05	5.34e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—meningioma	3.73e-05	5.28e-05	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—meningioma	3.67e-05	5.21e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—meningioma	3.58e-05	5.08e-05	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—meningioma	3.58e-05	5.08e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—meningioma	3.54e-05	5.02e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—meningioma	3.53e-05	5.01e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—meningioma	3.48e-05	4.93e-05	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—meningioma	3.4e-05	4.83e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—meningioma	3.39e-05	4.81e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—meningioma	3.38e-05	4.79e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—meningioma	3.35e-05	4.74e-05	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—meningioma	3.32e-05	4.71e-05	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—meningioma	3.31e-05	4.69e-05	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—meningioma	3.15e-05	4.46e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—meningioma	3.13e-05	4.44e-05	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—meningioma	3.13e-05	4.44e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—meningioma	3.05e-05	4.33e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—meningioma	3.05e-05	4.32e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—meningioma	2.88e-05	4.09e-05	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—meningioma	2.85e-05	4.04e-05	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—meningioma	2.83e-05	4.01e-05	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—meningioma	2.72e-05	3.86e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—meningioma	2.6e-05	3.68e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—meningioma	2.59e-05	3.68e-05	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—meningioma	2.57e-05	3.65e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—meningioma	2.54e-05	3.61e-05	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—meningioma	2.51e-05	3.56e-05	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—meningioma	2.43e-05	3.45e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—meningioma	2.41e-05	3.42e-05	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—meningioma	2.4e-05	3.41e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—meningioma	2.2e-05	3.11e-05	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—meningioma	2.19e-05	3.11e-05	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—meningioma	2.15e-05	3.04e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—meningioma	2.08e-05	2.96e-05	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—meningioma	2.04e-05	2.89e-05	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—meningioma	2.04e-05	2.89e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—meningioma	1.91e-05	2.71e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—meningioma	1.8e-05	2.56e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—meningioma	1.79e-05	2.53e-05	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—meningioma	1.76e-05	2.5e-05	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—meningioma	1.49e-05	2.12e-05	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—meningioma	1.27e-05	1.79e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—meningioma	1.18e-05	1.67e-05	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—meningioma	1.1e-05	1.56e-05	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—meningioma	1.04e-05	1.47e-05	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—meningioma	1.03e-05	1.46e-05	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—meningioma	6.79e-06	9.63e-06	CbGpPWpGaD
